In the group with high levels of IRF1 activation, inhibition of mTOR and Wnt/β-catenin signaling pathways was observed, which was previously shown to be associated with poor prognosis and a more aggressive immune phenotype in melanoma. The gene discussed is IRF1; the disease is melanoma.